Luspatercept for rare inherited anemias
Part of Blood & lymphatic clinical trials.
This trial tests a drug called luspatercept to see if it can improve red blood cell production in people with certain rare inherited anemias. If you have one of these anemias and have low hemoglobin, this study might help you reduce or avoid blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these rare anemias: sideroblastic anemia, congenital dyserythropoietic anemia, or Diamond-Blackfan anemia (but not needing regular transfusions).
- Your diagnosis must be confirmed by a genetic test (or for sideroblastic anemia, sometimes by a specialist if no gene is found).
- Your hemoglobin must be below 10.5 g/dL, or you need 6 to 20 blood transfusions in the last 24 weeks (for non-DBA types).
- Your kidney and liver function must be adequate, and you must be able to care for yourself (ECOG score 0-2).
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests a drug called luspatercept (Reblozyl) as the first treatment for people with a bone marrow disorder that causes low blood counts and requires regular blood transfusions. The drug may help reduce the need for transfusions by improving red blood cell production.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This study tests a drug called luspatercept for people with a mild form of aplastic anemia who still need frequent blood transfusions. Luspatercept may help your body make more red blood cells, reducing the need for transfusions and improving your energy.
This trial tests whether a medication called luspatercept can help raise red blood cells faster after a stem cell transplant for blood cancer. It aims to reduce severe anemia and improve recovery.
Hear when a new Hereditary Red Blood Cell Disorder (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.